AR082076A2 - Succinato de o-desmetil-venlafaxina, composicion farmaceutica que lo comprende, forma de dosificacion que lo comprende, su uso en la manufactura de un medicamento, y metodo para prepararlo - Google Patents
Succinato de o-desmetil-venlafaxina, composicion farmaceutica que lo comprende, forma de dosificacion que lo comprende, su uso en la manufactura de un medicamento, y metodo para prepararloInfo
- Publication number
- AR082076A2 AR082076A2 ARP110102372A ARP110102372A AR082076A2 AR 082076 A2 AR082076 A2 AR 082076A2 AR P110102372 A ARP110102372 A AR P110102372A AR P110102372 A ARP110102372 A AR P110102372A AR 082076 A2 AR082076 A2 AR 082076A2
- Authority
- AR
- Argentina
- Prior art keywords
- venlafaxine
- desmethyl
- disorder
- crystalline
- understands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se provee una sal de la O-desmetil venlafaxina, el succinato de O-desmetilvenlafaxina. También se proveen composiciones farmacéuticas, formas de dosificación, métodos para prepararla y usos de la misma.Reivindicación 7: Un compuesto de la reivindicación 6, caracterizado porque el compuesto exhibe un patrón de difracción de Rayos X de polvo que tiene picos característicos expresados en grados 2q (± 0,2º 2q) a 10,36, 13,74, 14,40, 14,68, 14,96, 16,75, 17,48, 17,76, 19,26, 20,42, 20,74, 22,55, 23,58, 23,82, 24,92, 26,00, 31,86 y 32,42. Reivindicación 11: Una composición farmacéutica caracterizada porque comprende succinato de O-desmetil venlafaxina cristalino según cualquiera de las reivindicaciones 1 a 10 y un vehículo o excipiente farmacéuticamente aceptable. Reivindicación 13: Una forma de dosificación farmacéutica caracterizada porque comprende una cantidad terapéuticamente efectiva de succinato de O-desmetil venlafaxina cristalino según cualquiera de las reivindicaciones 1 a 10 y un vehículo o excipiente farmacéuticamente aceptable. Reivindicación 23: Uso del succinato de O-desmetil-venlafaxina cristalino según cualquiera de las reivindicaciones 1 a 10 caracterizado porque es en la manufactura de un medicamento para (i) el tratamiento de depresión, ansiedad, trastorno de pánico, trastorno de ansiedad generalizada, trastorno de estrés post-traumático, fibromialgia, agorofobia, trastorno de déficit de atención, trastorno compulsivo obsesivo, trastorno de ansiedad social, autismo, esquizofrenia, obesidad, anorexia nerviosa, bulimia nerviosa, Síndrome de Gilles de la Tourette, rubor vasomotor, adicción a la cocaína y al alcohol, disfunción sexual, trastorno de personalidad fronteriza, síndrome de fatiga crónica, incontinencia urinaria, dolor, síndrome de Shy Drager, síndrome de Raynaud, enfermedad de Parkinson y epilepsia en un paciente; (ii) mejorar la cognición o tratar el deterioro cognitivo en un paciente; (iii) dejar de fumar u otros usos del tabaco en un paciente; (iv) tratar el desorden disfórico premenstrual en una mujer o la amenorrea hipotalámica en una mujer deprimida o no deprimida. Reivindicación 24: Un método para preparar succinato de O-desmetil-venlafaxina cristalino de acuerdo con la reivindicación 1, caracterizado porque comprende los pasos de: (a) desmetilación de venlafaxina o una sal de la misma con una sal de metal alcalino de un trialquil borohidruro para dar O-desmetil-venlafaxina; y (b) conversión de O-desmetil-venlafaxina en succinato de O-desmetil-venlafaxina; y (c) cristalizar directamente la sal cristalina a partir de un solvente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26821401P | 2001-02-12 | 2001-02-12 | |
US29796301P | 2001-06-13 | 2001-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082076A2 true AR082076A2 (es) | 2012-11-07 |
Family
ID=26952945
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100463A AR032671A1 (es) | 2001-02-12 | 2002-02-12 | Succinato novedoso de la o-desmetilvenlafaxina |
ARP110102372A AR082076A2 (es) | 2001-02-12 | 2011-07-01 | Succinato de o-desmetil-venlafaxina, composicion farmaceutica que lo comprende, forma de dosificacion que lo comprende, su uso en la manufactura de un medicamento, y metodo para prepararlo |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100463A AR032671A1 (es) | 2001-02-12 | 2002-02-12 | Succinato novedoso de la o-desmetilvenlafaxina |
Country Status (31)
Country | Link |
---|---|
US (5) | US6673838B2 (es) |
EP (3) | EP1360169B2 (es) |
JP (1) | JP4220243B2 (es) |
KR (1) | KR100875610B1 (es) |
CN (2) | CN100567253C (es) |
AR (2) | AR032671A1 (es) |
AT (1) | ATE369330T1 (es) |
AU (1) | AU2002250058B2 (es) |
BR (1) | BR0207157A (es) |
CA (2) | CA2436668C (es) |
CY (1) | CY1106952T1 (es) |
DE (1) | DE60221642T3 (es) |
DK (1) | DK1360169T3 (es) |
EA (1) | EA011451B1 (es) |
ES (1) | ES2290281T5 (es) |
HK (1) | HK1057885A1 (es) |
HN (1) | HN2002000030A (es) |
HU (1) | HUP0303128A3 (es) |
IL (4) | IL157340A0 (es) |
MX (1) | MXPA03007043A (es) |
NO (1) | NO328807B1 (es) |
NZ (1) | NZ539791A (es) |
PA (1) | PA8539901A1 (es) |
PE (1) | PE20020877A1 (es) |
PL (2) | PL211788B1 (es) |
PT (1) | PT1360169E (es) |
SI (1) | SI1360169T1 (es) |
TW (1) | TWI318201B (es) |
UY (1) | UY27175A1 (es) |
WO (1) | WO2002064543A2 (es) |
ZA (1) | ZA200307116B (es) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9914826A (pt) | 1998-10-30 | 2001-11-06 | Ajinomoto Kk | Processo de cristalização de cristais de éster metìlico de n- [n-(3,3-dimetilbutil)-l-alfa-aspartil] -l-fenilalanina |
US6342533B1 (en) | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
PL350924A1 (en) * | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
HUP0303128A3 (en) * | 2001-02-12 | 2008-03-28 | Wyeth Corp | Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it |
US20050244498A1 (en) * | 2001-09-14 | 2005-11-03 | Biovail Laboratories, Inc. | Modified-release compositions of at least one form of venlafaxine |
UA80543C2 (en) | 2001-12-04 | 2007-10-10 | Wyeth Corp | Method for the preparation of o-desmethylvenlafaxine |
US20030190351A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon Bv | Extended release venlafaxine formulations |
BR0311693A (pt) * | 2002-06-10 | 2005-03-22 | Wyeth Corp | Sal de formato de o-desmetil-venlafaxina |
AU2003259373B2 (en) * | 2002-08-29 | 2006-03-09 | Dynogen Pharmaceuticals, Inc. | New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine |
US7345096B2 (en) * | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
JP2004359665A (ja) * | 2003-05-30 | 2004-12-24 | Rohm & Haas Co | 生体利用性増強剤を含有する治療組成物 |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
CA2554559A1 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7439280B2 (en) * | 2004-04-06 | 2008-10-21 | Basf Corporation | Lignocellulosic composite material and method for preparing the same |
MX2007000853A (es) * | 2004-07-22 | 2007-03-26 | Wyeth Corp | Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso. |
US20060020014A1 (en) * | 2004-07-22 | 2006-01-26 | Wyeth | Method for treating nervous system disorders and conditions |
KR20070045278A (ko) * | 2004-07-22 | 2007-05-02 | 와이어쓰 | 신경계 질환 및 장애의 치료 방법 |
EP2258376B1 (en) | 2004-07-27 | 2019-02-27 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
WO2006094083A1 (en) * | 2005-02-28 | 2006-09-08 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
EP1863464B1 (en) * | 2005-03-31 | 2009-11-11 | Wyeth | O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
CN1955159B (zh) | 2005-06-17 | 2010-11-24 | 山东绿叶制药有限公司 | 用于阻断5-羟色胺以及去甲基肾上腺素再摄取的化合物,其制备方法及其用途 |
WO2007005961A2 (en) * | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
WO2007011594A2 (en) * | 2005-07-15 | 2007-01-25 | Wyeth | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof |
US7595340B2 (en) | 2005-07-15 | 2009-09-29 | Wyeth | Serotonin and norepinephrine reuptake inhibitor and uses thereof |
US7687520B2 (en) | 2005-07-15 | 2010-03-30 | Wyeth Llc | Serotonin and norepinephrine reuptake inhibitors and uses thereof |
JP2009502798A (ja) * | 2005-07-21 | 2009-01-29 | ワイス | 神経系障害および状態の処置方法 |
GT200600397A (es) * | 2005-09-07 | 2007-08-28 | Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales | |
GT200600396A (es) * | 2005-09-07 | 2007-04-23 | Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales | |
US7456317B2 (en) * | 2005-12-01 | 2008-11-25 | Auspex Pharmaceuticals | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
CN1332946C (zh) * | 2005-10-21 | 2007-08-22 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 作用于中枢神经系统的前药 |
WO2007067501A1 (en) * | 2005-12-05 | 2007-06-14 | Wyeth | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols |
EP1973866A1 (en) * | 2005-12-20 | 2008-10-01 | Synthon B.V. | Process for making desvenlafaxine |
MX2007016179A (es) * | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
EP2007708A1 (en) | 2006-04-17 | 2008-12-31 | Teva Pharmaceutical Industries Ltd | Substantially pure o-desmethylvenlafaxine and processes for preparing it |
WO2007136650A2 (en) * | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
US20090137846A1 (en) * | 2006-07-26 | 2009-05-28 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-Desmethylvenlafaxine |
US7605290B2 (en) * | 2006-07-26 | 2009-10-20 | Teva Pharmaceutical Industries Ltd. | Processes for the synthesis of O-desmethylvenlafaxine |
US20090069601A1 (en) * | 2006-07-26 | 2009-03-12 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-desmethylvenlafaxine |
WO2008013993A2 (en) * | 2006-07-26 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Processes for the synthesis of o-desmethylvenlafaxine |
US20080221356A1 (en) * | 2006-07-26 | 2008-09-11 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-desmethylvenlafaxine |
US20100121108A1 (en) * | 2006-08-04 | 2010-05-13 | Medichem, S.A. | Process for synthesizing desvenlafaxine free base and salts or solvates thereof |
CA2659295A1 (en) * | 2006-08-08 | 2008-02-14 | Generics [Uk] Limited | Novel hydrate form of o-desmethyl venlafaxine succinate |
CA2665381A1 (en) * | 2006-10-18 | 2008-04-24 | Generics [Uk] Limited | Polymorphs of o-desmethyl venlafaxine succinate |
PE20081138A1 (es) * | 2006-10-25 | 2008-09-18 | Wyeth Corp | Metabolitos aislados de hidroxi y n-oxido y derivados de desmetil venlafaxina y metodos de tratamiento |
ATE502028T1 (de) * | 2006-12-21 | 2011-04-15 | Pfizer Prod Inc | Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)- 1h-pyrazol-3-yl)phenoxy)methyl)chinolin |
AR064507A1 (es) * | 2006-12-22 | 2009-04-08 | Medichem Sa | Nuevas formas solidas cristalinas de forma base de o-desvenlafaxina |
US7820716B2 (en) * | 2007-01-08 | 2010-10-26 | Mai De Ltd | Crystalline polymorphs of desvenlafaxine succinate and their preparations |
WO2008090465A2 (en) * | 2007-01-22 | 2008-07-31 | Medichem, S.A. | Process for synthesizing desvenlafaxine free base and salts or salvates thereof |
AU2008211711A1 (en) * | 2007-01-31 | 2008-08-07 | Generics [Uk] Limited | Process for the preparation of O-desmethyl venlafaxine |
NZ599480A (en) * | 2007-02-21 | 2013-10-25 | Sunovion Pharmaceuticals Inc | Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof |
WO2008110338A1 (en) * | 2007-03-09 | 2008-09-18 | Synthon B.V. | Polymorph of desvenlafaxine succinate |
IN2009DN05509A (es) * | 2007-03-14 | 2010-04-30 | Teva Pharma | |
US20080234257A1 (en) | 2007-03-15 | 2008-09-25 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
US20090012182A1 (en) * | 2007-06-15 | 2009-01-08 | Alexandr Jegorov | Crystal forms of O-desmethylvenlafaxine succinate |
BRPI0812501A2 (pt) * | 2007-07-12 | 2015-06-16 | Reddys Lab Ltd Dr | O-desmetil venlafaxina |
IN2007CH01519A (es) * | 2007-07-16 | 2009-09-11 | Matrix Lab Ltd | |
WO2009017813A1 (en) * | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
US20090076162A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched desvenlafaxine |
JP2011500605A (ja) * | 2007-10-16 | 2011-01-06 | アルファファーム ピーティーワイ リミテッド | 制御放出医薬配合物 |
WO2009053840A2 (en) * | 2007-10-22 | 2009-04-30 | Actavis Group Ptc Ehf | Solid forms of (±)-o-desmethylvenlafaxine salts |
CN101952240A (zh) | 2007-10-26 | 2011-01-19 | 基因里克斯(英国)有限公司 | 用于制备o-去甲基文拉法辛的方法 |
CA2706775A1 (en) * | 2007-11-26 | 2009-06-04 | Teva Pharmaceutical Industries Ltd. | Crystal forms of o-desmethylvenlafaxine fumarate |
EP2085377A1 (en) | 2008-01-29 | 2009-08-05 | LEK Pharmaceuticals D.D. | Novel salts of O-desmethyl-venlafaxine |
EP2262758A4 (en) * | 2008-03-12 | 2011-12-07 | Reddys Lab Ltd Dr | O-desmethylvenlafaxine SALTS |
WO2009118758A2 (en) * | 2008-03-24 | 2009-10-01 | Sun Pharmaceutical Industries Ltd. | Novel crystalline forms of desvenlafaxine succinate |
IN2008CH00818A (es) * | 2008-04-01 | 2009-10-09 | Actavis Group Ptc Ehf | |
KR100965527B1 (ko) * | 2008-05-08 | 2010-06-23 | 제일약품주식회사 | 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물 |
EP2119696A1 (en) * | 2008-05-16 | 2009-11-18 | Krka | Preparation of O-desmethylvenlafaxine salts |
EP2119695A1 (en) | 2008-05-16 | 2009-11-18 | Krka | Preparation of O-desmethylvenlafaxine salts |
WO2010008735A2 (en) * | 2008-06-16 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Solid states of o-desmethylvenlaf axine salts |
US8658617B2 (en) | 2008-07-08 | 2014-02-25 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
US20100016638A1 (en) * | 2008-07-21 | 2010-01-21 | Zdenko Hamersak | Method for preparation of o-desmethylvenlafaxine using polythiolates |
AU2009275667A1 (en) * | 2008-07-30 | 2010-02-04 | Generics [Uk] Limited | Process for the preparation of O-desmethylvenlafaxine |
KR101041960B1 (ko) * | 2008-08-14 | 2011-06-16 | 주식회사 루미맥스테크놀러지 | 파워 led를 구비하는 램프 장치 |
EP2191822A1 (en) * | 2008-11-26 | 2010-06-02 | LEK Pharmaceuticals d.d. | Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine |
CZ301503B6 (cs) * | 2008-11-27 | 2010-03-24 | Zentiva, A. S. | Zpusob prípravy desvenlafaxinu a jeho solí |
ES2343050B1 (es) * | 2008-12-16 | 2011-06-14 | Chemo Iberica, S.A. | Procedimiento para la preparacion de desvenlafaxina y sus sales de adicion de acido farmaceuticamente aceptables. |
CZ200969A3 (cs) * | 2009-02-06 | 2010-06-30 | Zentiva, K.S. | Nové soli desvenlafaxinu a zpusob jejich prípravy |
CZ2009454A3 (cs) | 2009-07-15 | 2010-11-10 | Zentiva, K. S. | Zpusob prípravy desvenlafaxinu a jeho solí |
AU2010272377A1 (en) | 2009-07-16 | 2012-01-19 | Cipla Limited | Process for the preparation of O-desmethyl venlafaxine and intermediate for use therein |
US20110098506A1 (en) * | 2009-10-26 | 2011-04-28 | Intas Pharmaceuticals Limited | Method of preparing o-desmethylvenlafaxine |
WO2011072703A1 (en) | 2009-12-16 | 2011-06-23 | Pharmathen S.A. | Process for the preparation of o-desmethyl-venlafaxine and salts thereof |
US20110184067A1 (en) * | 2010-01-25 | 2011-07-28 | Intas Pharmaceuticals Ltd. | O-desmethylvenlafaxine succinate polymorph & process for preparing thereof |
WO2011121452A2 (en) * | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
BR112012024576A2 (pt) * | 2010-03-31 | 2016-05-31 | Wockhardt Ltd | composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição |
CZ303249B6 (cs) * | 2010-04-06 | 2012-06-20 | Zentiva, K.S. | Zpusob výroby 4-(2-(substituovaných)-1-(1-hydroxycyklohexyl)ethyl)fenolu O-demethylací jejich methyletheru pomocí nepáchnoucích aromatických thiolu |
CN102212014B (zh) * | 2010-04-09 | 2013-12-25 | 江苏豪森医药集团有限公司 | O-去甲基-文拉法辛的谷氨酸盐的晶型、其制备方法及其在医药上的应用 |
AU2011251747B2 (en) | 2010-05-14 | 2014-08-07 | Alembic Limited | Extended release formulations of desvenlafaxine base |
CN102249936B (zh) * | 2010-05-19 | 2014-09-17 | 江苏豪森医药集团有限公司 | O-去甲基文拉法辛盐酸盐的水合物及其制备方法 |
CA2812227C (en) | 2010-10-01 | 2015-11-24 | Shan Dong Luye Pharmaceutical Co., Ltd. | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same |
US8933123B2 (en) | 2010-10-08 | 2015-01-13 | Cadila Healthcare Limited | Polymorphic forms of O-desmethyl-venlafaxine succinate |
BR112013023810A2 (pt) | 2011-03-17 | 2016-12-13 | Lupin Ltd | composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina |
MX2013011884A (es) | 2011-04-12 | 2013-11-21 | Lupin Ltd | Composiciones farmaceuticas de liberacion modificada de desvenlafaxina. |
US8481596B2 (en) | 2011-06-08 | 2013-07-09 | Lupin Limited | Polymomorph of desvenlafaxine benzoate |
UY35091A (es) * | 2012-10-24 | 2014-05-30 | Onyx Therapeutics Inc | Formulaciones de liberacion modificada para oprozomib |
CN104666291A (zh) * | 2013-11-26 | 2015-06-03 | 山东绿叶制药有限公司 | 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用 |
CN104352469A (zh) * | 2014-11-20 | 2015-02-18 | 哈尔滨圣吉药业股份有限公司 | 一种琥珀酸去甲文拉法辛缓释片及其制备方法 |
CN106146323B (zh) * | 2015-04-03 | 2021-05-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种琥珀酸去甲文拉法辛一水合物新晶型及制备方法 |
MX367362B (es) | 2016-06-29 | 2019-08-16 | Alparis Sa De Cv | Nuevas formas solidas de desvenlafaxina. |
ES2961706T3 (es) * | 2017-02-09 | 2024-03-13 | R L Finechem Private Ltd | Un proceso para la preparación de 1-[2-(dimetilamino)-1-(4-hidroxifenil)etil]-ciclohexanol y sales del mismo |
CN107082745A (zh) * | 2017-04-21 | 2017-08-22 | 上海华源医药科技发展有限公司 | 一种改进的ⅰ型去甲文拉法辛琥珀酸盐的生产方法 |
US11400051B2 (en) * | 2017-07-11 | 2022-08-02 | Universal Stabilization Technologies, Inc. | Method for preserving biopharmaceuticals |
PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
WO2019031902A2 (ko) | 2017-08-11 | 2019-02-14 | (주)아모레퍼시픽 | (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물 |
TR201820634A2 (tr) | 2018-12-27 | 2020-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Desvenlafaksi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE56324B1 (en) * | 1982-12-13 | 1991-06-19 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
US4761501A (en) * | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
GB8902209D0 (en) | 1989-02-01 | 1989-03-22 | Wyeth John And Brother Limited | Preparation of cyclohexanol derivatives and novel thioamide intermediates |
IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
EP0647134A4 (en) | 1992-06-23 | 1997-07-30 | Sepracor Inc | METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-). |
EP0708639A4 (en) | 1992-06-23 | 1997-08-20 | Sepracor Inc | METHOD AND COMPOSITIONS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTTRAMINE |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
EP1153603B1 (en) * | 1993-06-28 | 2006-10-18 | Wyeth | New treatments using phenethylamine derivatives |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
ES2185683T3 (es) * | 1994-02-14 | 2003-05-01 | Wyeth Corp | Venlafaxina y sus analogos para inducir una mejora de las funciones cognitivas. |
US5594586A (en) * | 1994-05-02 | 1997-01-14 | The United States Of America As Represented By The Secretary Of The Air Force | Photorefractive limiting quadratic processor |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5506270A (en) † | 1995-01-30 | 1996-04-09 | American Home Products Corporation | Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women |
US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
EP0912577A2 (en) † | 1996-05-21 | 1999-05-06 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Novel methods of o-demethylation and n-deprotection |
WO1999016417A1 (en) † | 1997-10-01 | 1999-04-08 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US6197828B1 (en) | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
US6342533B1 (en) * | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
PL350924A1 (en) * | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
JP4722295B2 (ja) † | 1999-05-27 | 2011-07-13 | エイカスフィアー・インコーポレーテッド | 多孔性薬剤マトリクスおよびその製造方法 |
WO2000076955A1 (en) * | 1999-06-15 | 2000-12-21 | American Home Products Corporation | Enantiomers of o-desmethyl venlafaxine |
US20020022662A1 (en) | 1999-06-15 | 2002-02-21 | American Home Products Corporation | Enantiomers of O-desmethyl venlafaxine |
HUP0303128A3 (en) * | 2001-02-12 | 2008-03-28 | Wyeth Corp | Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it |
UA80543C2 (en) * | 2001-12-04 | 2007-10-10 | Wyeth Corp | Method for the preparation of o-desmethylvenlafaxine |
BR0311693A (pt) | 2002-06-10 | 2005-03-22 | Wyeth Corp | Sal de formato de o-desmetil-venlafaxina |
TWI306092B (en) | 2003-03-11 | 2009-02-11 | Wyeth Corp | Process for preparation of phenethylamine derivatives |
CA2554559A1 (en) | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
-
2002
- 2002-02-11 HU HU0303128A patent/HUP0303128A3/hu unknown
- 2002-02-11 CA CA002436668A patent/CA2436668C/en not_active Expired - Lifetime
- 2002-02-11 MX MXPA03007043A patent/MXPA03007043A/es active IP Right Grant
- 2002-02-11 CN CNB028081129A patent/CN100567253C/zh not_active Expired - Lifetime
- 2002-02-11 AT AT02718949T patent/ATE369330T1/de active
- 2002-02-11 DK DK02718949T patent/DK1360169T3/da active
- 2002-02-11 EP EP02718949.7A patent/EP1360169B2/en not_active Expired - Lifetime
- 2002-02-11 IL IL15734002A patent/IL157340A0/xx unknown
- 2002-02-11 PL PL364605A patent/PL211788B1/pl unknown
- 2002-02-11 JP JP2002564477A patent/JP4220243B2/ja not_active Expired - Lifetime
- 2002-02-11 WO PCT/US2002/004103 patent/WO2002064543A2/en active Application Filing
- 2002-02-11 BR BR0207157-6A patent/BR0207157A/pt not_active Application Discontinuation
- 2002-02-11 CA CA002666611A patent/CA2666611A1/en not_active Abandoned
- 2002-02-11 KR KR1020037010561A patent/KR100875610B1/ko active IP Right Review Request
- 2002-02-11 PE PE2002000105A patent/PE20020877A1/es active IP Right Grant
- 2002-02-11 EA EA200300873A patent/EA011451B1/ru not_active IP Right Cessation
- 2002-02-11 ES ES02718949.7T patent/ES2290281T5/es not_active Expired - Lifetime
- 2002-02-11 EP EP10177304A patent/EP2319826A1/en not_active Withdrawn
- 2002-02-11 PT PT02718949T patent/PT1360169E/pt unknown
- 2002-02-11 SI SI200230609T patent/SI1360169T1/sl unknown
- 2002-02-11 CN CN200910206182A patent/CN101671260A/zh active Pending
- 2002-02-11 AU AU2002250058A patent/AU2002250058B2/en not_active Expired
- 2002-02-11 EP EP07014868A patent/EP1864967A1/en not_active Withdrawn
- 2002-02-11 NZ NZ539791A patent/NZ539791A/en not_active IP Right Cessation
- 2002-02-11 DE DE60221642.7T patent/DE60221642T3/de not_active Expired - Lifetime
- 2002-02-11 HN HN2002000030A patent/HN2002000030A/es unknown
- 2002-02-11 US US10/073,743 patent/US6673838B2/en not_active Expired - Lifetime
- 2002-02-11 PL PL396568A patent/PL212943B1/pl unknown
- 2002-02-12 AR ARP020100463A patent/AR032671A1/es not_active Application Discontinuation
- 2002-02-13 UY UY27175A patent/UY27175A1/es active IP Right Grant
- 2002-02-14 PA PA20028539901A patent/PA8539901A1/es unknown
- 2002-02-15 TW TW091102559A patent/TWI318201B/zh not_active IP Right Cessation
-
2003
- 2003-08-11 NO NO20033538A patent/NO328807B1/no not_active IP Right Cessation
- 2003-08-11 IL IL157340A patent/IL157340A/en active IP Right Grant
- 2003-09-04 US US10/654,756 patent/US20040044241A1/en not_active Abandoned
- 2003-09-11 ZA ZA2003/07116A patent/ZA200307116B/en unknown
-
2004
- 2004-02-05 HK HK04100742A patent/HK1057885A1/xx not_active IP Right Cessation
- 2004-11-10 US US10/985,292 patent/US7026508B2/en not_active Expired - Fee Related
-
2006
- 2006-01-18 US US11/334,223 patent/US7291347B2/en not_active Expired - Lifetime
-
2007
- 2007-08-20 US US11/841,638 patent/US20090018208A1/en not_active Abandoned
- 2007-10-22 CY CY20071101362T patent/CY1106952T1/el unknown
-
2009
- 2009-08-05 IL IL200255A patent/IL200255A/en active IP Right Grant
-
2010
- 2010-11-18 IL IL209444A patent/IL209444A/en active IP Right Grant
-
2011
- 2011-07-01 AR ARP110102372A patent/AR082076A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR082076A2 (es) | Succinato de o-desmetil-venlafaxina, composicion farmaceutica que lo comprende, forma de dosificacion que lo comprende, su uso en la manufactura de un medicamento, y metodo para prepararlo | |
AU774408B2 (en) | Derivatives of (-)-venlafaxine and methods of preparing and using the same | |
US6197828B1 (en) | Derivatives of (+)-venlafaxine and methods of preparing and using the same | |
EP1165487A1 (en) | Derivatives of venlafaxine and methods of preparing and using the same | |
US20090326075A1 (en) | Enantiomers of o-desmethyl venlafaxine | |
RU2007149183A (ru) | Высокоселективный двойной ингибитор обратного захвата серотонина и норэпинефрина и его применение | |
DE19937537A1 (de) | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate | |
Giannini et al. | Khat: another drug of abuse? | |
AU2002239572B2 (en) | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | |
AU2002239572A1 (en) | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | |
CN1290816C (zh) | 贯叶金丝桃素衍生物,其应用以及包含它们的制剂 | |
CN1795158A (zh) | 可用于治疗阿尔茨海默病的化合物和含有它们的制剂 | |
CN100343270C (zh) | 一种从天然植物中提取治疗恶性肿瘤产品的生产工艺 | |
EP1142859A3 (en) | Process for producing optically active 3,7-dimethyl-6-octenol and process for producing intermediate therefor | |
EP1232141B1 (en) | Ethers of o-desmethyl venlafaxine | |
Simakova et al. | The catalytic method of verbanol preparation with controlled isomer distribution starting from renewable material α-pinene | |
BR0314280A (pt) | Composto; método de tratamento de um indivìduo acometido por uma condição de depressão, ansiedade, distúrbios do pânico, de tensão pós-traumática, disfórico pré-menstrual, de deficiência da atenção, obsessivos-compulsivos e alimentares, obesidade, rubor vasomotor, dependência de álcool e cocaìna e disfunção sexual; composição farmacêutica e uso do mesmo | |
WO2000076956A2 (en) | Enantiomers of n-desmethyl venlafaxine | |
US20020165284A1 (en) | Enantiomers of N-desmethyl venlafaxine | |
CN116535325A (zh) | 一种氘代安非他酮及其制备方法 | |
MITSCHER | DANIEL LEDNICER | |
AU2005200129A1 (en) | Derivatives of (+)-venlafaxine and methods of preparing and using the same | |
AU3106200A (en) | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |